CFRA Upgrades Infosys with GenAI Integration and Valuation Insights
Investing.com | Author Aayush Khanna
Published Apr 24, 2024 19:06
In a recent report, CFRA has upgraded Infosys (NS:INFY) stock from Hold to Buy, signaling increased confidence in the company's future performance. Despite maintaining a target price of US$20, CFRA has raised its valuation target to 25 times FY 25 (Mar.) earnings per share (EPS), up from 23 times, exceeding the 5-year mean price-to-earnings (P/E) ratio of 24 times.
While trimming FY 25 EPS by 7% to US$0.79, CFRA has initiated FY 26 EPS at US$0.88. Infosys' FY 24 results were in line with expectations, with EPS growing by 6% to US$0.76 and revenue by 2% to US$18.6 billion. Although operating profit margin (OPM) narrowed slightly by 0.4% to 20.7%, primarily due to salary hikes since November 2023, it was mitigated by an 8% increase in revenue per core employee.
A significant highlight is Infosys' achievement of US$17.7 billion in large deal wins in FY 24 (Mar-Q: US$4.5 billion), a substantial rise from FY 23's US$9.8 billion. CFRA anticipates the revenue growth impact to materialize in FY 26 as corporate spending potentially shifts towards discretionary spending.
CFRA's increased optimism stems from Infosys' adoption of generative AI (genAI), which has the potential to enhance revenue across various business areas and improve margins by automating coding workload. This strategic move towards genAI aligns with Infosys' focus on innovation and technological advancement.
Image Source: InvestingPro+
Currently, Infosys ADR (listed in the US) is trading at US$17.17 and InvestingPro’s fair value feature is estimating an upside potential of 2.2% to 17.55. Its counterpart - Indian-listed shares are trading at INR 1,433.6, with an upside of 2.3% to INR 1,467.
However, analysts that are covering this counter are more bullish and a total of 43 of them are estimating an average upside till INR 1,595. A financial health score of 4 out of 5 also builds up confidence in the counter. Investors can keep a tab on this score as their primary line of check for stocks that eventually qualify for portfolio addition.
The fair value feature is quite helpful in determining whether the stock is overvalued or undervalued, further helping in maintaining the portfolio-level valuations in check. Investors can also check the prices and valuations of the ADRs of Indian companies in InvestingPro.
You can check the fair value, financial health score, watch prices of ADRs, and take bite-sized information from ProTips, all at a limited-time discount of up to 69%, for INR 216/month. Aayush Khanna
Get The App
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.